First-line treatment of metastatic breast cancer

Anti-Cancer Drugs

Volumn 7, Issue SUPPL. 2, 1996, Pages 9-12

  Trudeau, M E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

docetaxel (Taxotere ); first line treatment; metastatic breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL;

BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; HUMAN; METASTASIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0029792587     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199608002-00003     Document Type: Conference Paper

References (30)

1. Tannock I, Boyd N, De Boer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377-1387.
2. Coates A, Gebski V, Bishop JF, et al. Improving the quality of life during chemotherapy for advanced breast cancer. N Engl J Med 1987; 317: 1490-1495.
3. Coates A, Gebski V, Signorini D, et al. Prognostic value of quality of life scores during chemotherapy for advanced breast cancer. J Clin Oncol 1992; 10: 1833-1838.
4. Hayes DF, Henderson IC, Shapiro CL. Treatment of metastatic breast cancer: present and future prospects. Semin Oncol 1995; 22: 5-19.
5. Ross MB, Buzdar AU, Smith TL, et al. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy: comparison of consecutive series of patients in 1950's, 1960's, and 1970's. Cancer 1985; 55: 341-346.
6. Henderson IC. Chemotherapy for metastatic disease. In: Harris JR, Hellman S, Henderson IC, et al., eds. Breast diseases (2nd edn). Philadelphia, PA: Lippincott; 1991: 604-665.
7. Dunphy FR, Spitzer G, Rossiter Fornoff JE et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 1994; 73: 2157-2167.
8. Falkson G, Gelman R, Falkson CI et al. Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective eastern cooperative oncology group study. J Clin Oncol 1991; 9: 2153-2161.
9. Holmes FA, Walters RS, Theriault RL et al. Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-1805.
10. Wilson WH, Berg SI, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621-1629.
11. Abrams JS, Vena DA, Baltz J, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 1995; 13: 2056-2065.
12. Gianni L, Munzone E, Capri G, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by 3-hour infusion in patients with recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87: 1169-1175.
13. Seidman A, Hudis C, Tiersten A, et al Phase II trial of paclitaxel by three hour infusion as initial and as salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995; 13: 2575-2581.
14. Seidman A, Reichman BS, Crown JPA, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995b; 13: 1152-1159.
15. Vermorken JB, ten Bokkel-Huinink WW, Mandjes IAM. et al. High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial. Semin Oncol 1995; 22 (suppl 8): 16-22.
16. Canobbio L, Boccardo F, Pastorino G, et al. Phase 11 study of Navelbine in advanced breast cancer. Semin Oncol 1989; 16: 33-36.
17. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11: 1245-1252.
18. Romera A, Rabinovich MG, Vallejo CT, et al. Vinorelbine as a first-line chemotherapy for metastatic breast cancer. J Clin Oncol 1994; 12: 336-341.
19. Vandenberg TA, Pritchard KI, Eisenhauer EA, et al. Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1993; 11: 1241-1244.
20. Schornagel JH, van der Vegt S, de Graff A, et al. Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer. Ann Oncol 1992; 3: 549-552.
21. Possinger K, Kaufmann M, Helsing M, et al. Advanced breast cancer: a phase II trial with gemcitabine (GEM) [abstract 369]. Eur J Cancer 1995; 31A (suppl 5): S80.
22. Carmichael J, Possinger K, Philip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-2736.
23. Blackstein M, Vogel CL, Ambinder R, et al. Phase II study of gemcitabine in patients with metastatic breast cancer [abstract 135]. Proceedings of Asco 1996;15.
24. 2 every 3 weeks, as first line chemotherapy in advanced breast cancer. A second EORTC Clinical Screening Group Study [abstract 199]. Ann Oncol 1994; 5 (suppl 8): 40.
25. Trudeau MF, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 422-428.
26. Fumoleau P, Chevallier B, Dieras V, et al. Evaluation of two doses of Taxotere (docetaxel) as first line in advanced breast cancer: EORTC Clinical Screening Group report [abstract A622]. Breast Cancer Res Treat 1994; 32: 34. (abstrac
27. ten Bokkel-Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 527-532.
28. Seidman AD, Hudis C, Crown JP, et al. Phase II evaluation of Taxotere (RP 56976, NSC 628503) as initial chemotherapy for metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol 1993; 12: A52.
29. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Co-operative Group of the European Organization for Research and Treatment for Cancer. J Clin Oncol 1995; 13: 314-322.
30. Krakowsky I, Rios M, Fumoleau P, et al. Phase II first line chemotherapy (CT) study with docetaxel (Taxotere®) and prophylactic premedication of fluid retention (FR) in patients (pts) with metastatic (mts) or locally advanced breast cancer (ABC). EORTC Clinical Screening Group (CSG) [abstract 87]. Proc Am Soc Clin Oncol 1995; 14: 97.